- TLDR Biotech
- Archive
- Page 4
The Latest Biotech & Pharma Updates
Biotech & Pharma Updates | October 26 - 27, 2025
🧬 Innovent & Eli Lilly's mazdutide GLP-1/glucagon dual agonist outperforms Novo Nordisk’s semaglutide in Ph3 diabetes and obesity trial, MapLight Therapeutics raises $250M IPO to advance Cobenfy competitor for schizophrenia treatment, Hemab Therapeutics raises $157M Series C to advance blood clotting disorder treatments, Dyne Therapeutics shares surge 38% pre-market as Novartis' $12B Avidity buyout validates antisense space, WuXi AppTec + Hillhouse sign definitive agreement for latter's acquisition of WuXi's China-based clinical research services business, OpenAI + Thermo Fisher Scientific + Lundbeck partner on AI-powered drug development and clinical research operations, GSK + Syndivia partner on preclinical prostate cancer ADC in up to $357M deal
Biotech & Pharma Updates | October 23 - 26, 2025
🧬 Novartis acquires Avidity Biosciences for $12B to strengthen neuromuscular disease pipeline with RNA therapeutics, Eli Lilly acquires gene therapy developer Adverum Biotechnologies for up to $262M, Starna Therapeutics raises $47M Series B to power in-vivo CAR-T ambitions, Incyte touts positive Ph3b results for Opzelura (ruxolitinib) cream targeting JAK pathway in moderate atopic dermatitis, Kura Oncology + Kyowa Kirin collaboration reaches $30 million milestone for ziftomenib AML Phase 3 trials, Biogen, Vanqua Bio license anti-inflammatory C5aR1 antagonist ($70M upfront + $990M milestones) FDA approves Bayer's Lynkuet elinzanetant targeting NK1/NK3 receptors for moderate to severe vasomotor symptoms of menopause
Biotech & Pharma Updates | October 22 - 23, 2025
🧬 Cambrex's $120M Iowa facility investment (onshoring continues), AGC Biologics + Rarity PBC partner on "Bubble Baby Disease" gene therapy manufacturing, Kure Cells' $10M Pre-Series A for CGT "rapid-manufacturing platforms", Medivir out-licenses topical HDAC inhibitor to Biossil, Quarry Thera launches to develop next-generation molecular glue therapeutics, Harbour Biomed touts positive Ph2 data for porustobart + tislelizumab in colorectal cancer, Ventyx shares nearly double on obesity med's potential cardiovascular benefit
Biotech & Pharma Updates | October 21 - 22, 2025
🧬 Alkermes drops $2.1B on Avadel Pharma acquisition (excessive sleepiness therapeutics), Electra's $183M Series C powering rare inflammatory disease drug development, Flagship Pioneering launches Expedition Medicines with $50M to apply AI and covalent chemistry in cancer and immune diseases drug development, Sanofi's efdoralprin alfa meets Ph2 goals in alpha-1 antitrypsin deficiency, Novavax transfers Maryland HQ lease to AstraZeneca for $59.8M, AstraZeneca + Amgen's Tezspire lands EU approval in chronic rhinosinusitis with nasal polyps, Regeneron settles Eylea patent dispute with Celltrion - clearing biosimilar launch for December 2026
Biotech & Pharma Updates | October 20 - 21, 2025
🧬 Elevara Medicines launches with $70M + an in-licensed Ph2 ready asset, Axial Tx rebrands as Vertero Tx + $20M Series D, Chemify's $50M Series B to "digitize chemistry", AbbVie's Rinvoq beats Humira in Ph3 rheumatoid arthritis trial, Takeda, + Innovent Biologics partner on late-stage oncology medicines for solid tumors, Samsung Bioepis + Phrontline Biopharma partner on dual-payload ADC development involving undisclosed financials
Biotech & Pharma Updates | October 19 - 20, 2025
🧬 Roche's anti-cancer anti-CD20 lands lupus approval from FDA, Glaukos Epioxa lands FDA approval for rare eye disease, rumor mill sends Nektar Tx shares skyward over potential Eli Lilly acquisition, Kelun-Biotech unveils impressive lung cancer survival data for asset out-licensed to Merck & Co. outside Greater China, IDEAYA Biosciences' touts positive Ph2 data for darovasertib in eye cancer, Alto Neuroscience shares double after announcing plans to "accelerate" investigational depression med development after positive FDA meeting, Merck & Co. breaks ground on $3B Virginia small molecule plant
Biotech & Pharma Updates | October 16 - 19, 2025
🧬 Roche's Chugai's up to $1.1B deal with Rani Tx to make oral versions of injectables, Amgen + AstraZeneca nab Tezspire label extension into chronic rhinosinusitis with nasal polyps, Merck & Co. Keytruda + Pfizer & Astellas' Padcev delivers stellar Ph3 bladder cancer data, Roche signs up to $1.45B ADC deal with Hansoh Pharmaceutical, FDA hands out first batch of Commissioner’s Priority Vouchers
Biotech & Pharma Updates | October 15 - 16, 2025
🧬 Veradermics' $150M Series C for hair regrowth (the second $100+ hair-focused biotech raise this week), Kite Pharma goes deeper on in-vivo with up to $1.64B deal with Pregene Biotech, Dianthus Tx's up to $1B deal for Nanjing Leads Biolabs' bispecific, Adcytherix's $122M Series A powering ADC ambitions, Aicuris preps FDA filing after Ph3 win in treating immunocompromised patients with herpes, Merck & Co. delivers another Keytruda win with statistically significant OS benefit in platinum resistant ovarian cancer
Biotech & Pharma Updates | October 14 - 15, 2025
🧬 Tubulis' $361M Series C for ovarian + lung cancer ADC development, Pelage Pharmaceuticals closes $120M Series B targeting hair loss, Novo in-licenses Omeros's rare blood + kidney disease hopeful for up to $2.1B, Boehringer Ingelheim in-licenses ADC asset from AimedBio for up to $991M, Eli Lilly touts pair of Ph3 results for potential oral "foundational treatment" for type 2 diabetes, AstraZeneca drops $445M more on Texas-based Lokelma production site
Biotech & Pharma Updates | October 12 - 14, 2025
🧬 Kailera's $600M Series B (fueling obesity ambitions), Excellergy launches with $70 to control allergic reaction diseases "at the source", LTS Lohmann buys up US-based Renaissance Lakewood CDMO, Pfizer's Seagen acquisition continues delivering with another Ph3 win in HER2-positive breast cancer, Takeda + Nabla deepen partnership with up to $1B on the table (focused on AI-powered biologics discovery), Teva Pharmaceuticals + Medincell score FDA approval for once-monthly bipolar treatment
Biotech & Pharma Updates | October 9 - 12, 2025
🧬 BMS dives further into in-vivo cell therapy with $1.5B Orbital Tx buy, AstraZeneca agress to MFN pricing + joins TrumpRx, Ypsomed to build $248M NC-based manufacturing facility, J&J potentially buying Protagonist Tx in rumored well above $4B market value
Biotech & Pharma Updates | October 8 - 9, 2025
🧬 Novo Nordisk to buy Akero Tx for $4.7B, AstraZeneca kicks off construction on $4.5B Virginia-based API plant, Ascenta Capital announces inagurual $325M fund focused on platform biotech, Ono Pharma + Bristol Myers Squibb's EP4 antagonist touts positive Ph2 data in gastric cancer, AstraZeneca + Turbine partner on ADC discovery via experimental virtualization at scale, AviadoBio in-licenses rare eye disease gene therapy from China's UgeneX Therapeutics for up to $413M, Expedition Tx raises $165M Series A for DPP1 inhibitor in treating COPD